Article Text

Download PDFPDF
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity
  1. Daniel Mrak1,
  2. Selma Tobudic2,
  3. Maximilian Koblischke3,
  4. Marianne Graninger3,
  5. Helga Radner1,
  6. Daniela Sieghart1,
  7. Philipp Hofer4,
  8. Thomas Perkmann5,
  9. Helmuth Haslacher5,
  10. Renate Thalhammer5,
  11. Stefan Winkler2,
  12. Stephan Blüml1,
  13. Karin Stiasny3,
  14. Judith H Aberle3,
  15. Josef S Smolen1,
  16. Leonhard X Heinz1,
  17. Daniel Aletaha1,
  18. Michael Bonelli1
  1. 1 Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
  2. 2 Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria
  3. 3 Center for Virology, Medical University of Vienna, Vienna, Austria
  4. 4 Department of Pathology, Medical University of Vienna, Vienna, Austria
  5. 5 Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
  1. Correspondence to Professor Daniel Aletaha, Department of Medicine III, Division of Rheumatology, Medical University of Vienna, 1090 Vienna, Austria; daniel.aletaha{at}meduniwien.ac.at

Abstract

Objectives Evidence suggests that B cell-depleting therapy with rituximab (RTX) affects humoral immune response after vaccination. It remains unclear whether RTX-treated patients can develop a humoral and T-cell-mediated immune response against SARS-CoV-2 after immunisation.

Methods Patients under RTX treatment (n=74) were vaccinated twice with either mRNA-1273 or BNT162b2. Antibodies were quantified using the Elecsys Anti-SARS-CoV-2 S immunoassay against the receptor-binding domain (RBD) of the spike protein and neutralisation tests. SARS-CoV-2-specific T-cell responses were quantified by IFN-γ enzyme-linked immunosorbent spot assays. Prepandemic healthy individuals (n=5), as well as healthy individuals (n=10) vaccinated with BNT162b2, served as controls.

Results All healthy controls developed antibodies against the SARS-CoV-2 RBD of the spike protein, but only 39% of the patients under RTX treatment seroconverted. Antibodies against SARS-CoV-2 RBD significantly correlated with neutralising antibodies (τ=0.74, p<0.001). Patients without detectable CD19+ peripheral B cells (n=36) did not develop specific antibodies, except for one patient. Circulating B cells correlated with the levels of antibodies (τ=0.4, p<0.001). However, even patients with a low number of B cells (<1%) mounted detectable SARS-CoV-2-specific antibody responses. SARS-CoV-2-specific T cells were detected in 58% of the patients, independent of a humoral immune response.

Conclusions The data suggest that vaccination can induce SARS-CoV-2-specific antibodies in RTX-treated patients, once peripheral B cells at least partially repopulate. Moreover, SARS-CoV-2-specific T cells that evolved in more than half of the vaccinated patients may exert protective effects independent of humoral immune responses.

  • rituximab
  • vaccination
  • COVID-19

Data availability statement

Data are available upon reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information. All data relevant to the study are included in the report. All data are included in the article.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

https://bmj.com/coronavirus/usage

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available upon reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information. All data relevant to the study are included in the report. All data are included in the article.

View Full Text

Footnotes

  • Handling editor Gerd-Rüdiger R Burmester

  • DM and ST contributed equally.

  • Contributors All authors contributed to manuscript preparation. MB, DA, ST, DS, DM, SB and SW contributed to the study design. DM contributed to data analysis. TP, HH and KS performed antibody measurement. JHA, MK, PH and MG contributed to cellular assays, data analysis and manuscript preparation. LXH, HR and DM performed data analysis. MB, DA, JSS and DM contributed to manuscript preparation. RT determined leucocyte subsets.

  • Funding Work was supported by the Medical-Scientific fund of the Mayor of the federal capital Vienna to J.A. [grant Covid003].

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.